Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIg mechanisms in CIDP (PHARMACOPID)
NCT02404298Unknown
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2015
- Primary completion
- Jan 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of immune globulin in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), autoimmune disease, Systemic capillary leak syndrome (SCLS) and 1 more, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Gene expression profile at 3 weeks. Status: unknown.
02
Drugs
immune globulin
03
Conditions
chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)autoimmune diseaseSystemic capillary leak syndrome (SCLS)Myositis
Beyond the preview
Go deeper on NCT02404298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02404298.